Galectin Therapeutics reported $-11.29M in Operating Profit for its fiscal quarter ending in June of 2024.





Operating Profit Change Date
AbbVie USD 6.72B 1.99B Jun/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Galectin Therapeutics USD -11.29M 1.64M Jun/2024
Gilead Sciences USD 3.85B 1.17B Jun/2026
Immunic USD -23.33M 2.67M Dec/2025
Incyte USD 700.4M 376.22M Jun/2026
Merck USD 840M 2.72B Jun/2026